Abstract

REDUCTION IN ALLOPATHIC MEDICATION REQUIREMENT FOLLOWING STRUCTURED DIABETES CARE PROGRAM: A REALWORLD OBSERVATIONAL STUDY

*Dr. Aniket Ananda Kamble, Mr. Rohit Shivram Joshi

Abstract

Background: Type 2 diabetes mellitus (T2DM) remains a major non-communicable disease burden in India. Structured lifestyle-integrated diabetes care programs offer a promising strategy to reduce dependence on allopathic medications while improving metabolic control. Objective: To evaluate changes in allopathic medication requirements and key clinical parameters among T2DM patients enrolled in a structured diabetes care program at multi-site clinics in the Vidharbha region of Maharashtra, India. Methods: This real-world, prospective observational study enrolled 90 unique patients (64 males, 26 females; mean age 49.0 ± 11.1 years) across four clinics under the Vidharbha Regional Integrated Centre during April 2025 to March 2026. Patients were followed on structured care plans (DM Packages, Navjeevan Care Plan, Diet Care Plans). Allopathic medication dosage (tablets per day), anthropometric, and clinical laboratory parameters were recorded at baseline and follow-up. Paired t-tests were used for statistical comparisons. Results: Among the 43 patients on allopathic medications, mean daily dosage declined from 4.86 ± 5.76 to 3.81 ± 4.22 tablets/day; 16.3% achieved ≥50% medication reduction. Drug class–specific analysis identified 127 baseline prescriptions across 18 distinct therapeutic classes, reduced to 110 at follow-up (net −17; −13.4%). Insulin prescriptions declined by 50% (4→2), nitrate/antianginal prescriptions by 42.9% (7→4), and thyroid hormone prescriptions by 40% (5→3). Among oral anti-diabetic agents, DPP-4 inhibitor combinations declined 22.2%, while SGLT2 inhibitor+biguanide combinations increased 16.7%, reflecting guideline-concordant class switching. Significant improvements were observed in body weight (70.7 to 69.2 kg; p

Keywords: Type 2 diabetes mellitus; structured care program; medication reduction; HbA1c; drug class analysis; DPP-4 inhibitor; SGLT2 inhibitor; sulfonylurea; biguanide; insulin de-escalation; lifestyle intervention; Navjeevan; real-world study; India; Vidharbha.